

Adenosine A_{2A} Receptor and TNF- α Regulate the Circadian Machinery of the Human Monocytic THP-1 Cells

Miguel Perez-Aso,^{1,2} Jessica L. Feig,¹ Mediero Aránzazu,¹ and Bruce N. Cronstein¹

Abstract—Morning stiffness and increased symptoms of inflammatory arthritis are among the most common manifestations of rheumatoid arthritis (RA). Tumor necrosis alpha (TNF- α), an important mediator of inflammation in RA, regulates the circadian expression of clock proteins, and adenosine A_{2A} receptors (A_{2A}R) mediate many of the anti-inflammatory and antirheumatic actions of methotrexate, the cornerstone drug in the treatment of RA. We found that A_{2A}R activation and TNF- α activated the clock core loop of the human monocytic THP-1 cell line. We further observed that interleukin (IL)-10, but not IL-12, mRNA expression fluctuates in a circadian fashion and that TNF- α and A_{2A}R stimulation combined increased IL-10 expression. Interestingly, TNF- α , but not CGS21680, dramatically inhibited IL-12 mRNA expression. The demonstration that A_{2A}R and TNF- α regulate the intrinsic circadian clock in immune cells provides an explanation for both the pathologic changes in circadian rhythms in RA and for the adverse circadian effects of methotrexate, such as fatigue.

KEY WORDS: adenosine A2 receptor; TNF- α ; IL10; IL-12; clock genes; methotrexate.

INTRODUCTION

The daily rhythm of life follows from both the revolution of the earth on its axis and from the inherent circadian rhythms set by an internal clock apparatus. The internal clock in mammals and lower animals is organized by transcriptional machinery, namely the core clock genes *Clock*, *Bmal1*, *Period*, and *Cryptochrome* [1]. The master pacemaker apparatus resides in the hypothalamic suprachiasmatic nucleus, but virtually all cells in the body express genes related to periodicity [2–4]. In the immune system, many functions depend on the time of day, including variation in susceptibility to infection [5] and the course of such diseases as rheumatoid arthritis (RA [6]) or asthma [7]. In particular,

recent observations indicate that periodicity genes alter inflammation in animal models of arthritis, and inflammation leads to changes in expression of the pacemaker apparatus [8].

One of the most striking characteristics of RA, a chronic polyarthritis of unknown etiology, is the circadian fluctuation in symptoms [9–12]. In fact, morning stiffness, included in the diagnostic criteria of RA, is one of the most common complaints of afflicted patients [13, 14] and methotrexate (MTX) administration, the cornerstone in the treatment of RA, also manifests in perturbations of the circadian rhythm, primarily in the form of severe fatigue on the day that the weekly dose is taken [15, 16]. Moreover, the expression of proinflammatory cytokines [interleukin (IL)-1 β , IL-6, and tumor necrosis alpha (TNF- α)] and the classic disease specific marker rheumatoid factor exhibit characteristic rhythmic patterns [17–20].

The demonstration that low-dose, intermittent MTX is a potent and effective therapy for RA [21] was followed by investigations indicating that many of the therapeutic effects of MTX are mediated by adenosine [22, 23]. Adenosine potently diminishes the proinflammatory actions of inflammatory and immune cells via interaction with specific cell surface receptors [A₁R,

Electronic supplementary material The online version of this article (doi:10.1007/s10753-012-9530-x) contains supplementary material, which is available to authorized users.

¹ Division of Translational Medicine, Department of Medicine, New York University School of Medicine, 550 First Avenue, MSB255, New York, NY 10016, USA

² To whom correspondence should be addressed at Division of Translational Medicine, Department of Medicine, New York University School of Medicine, 550 First Avenue, MSB255, New York, NY 10016, USA. E-mail: Miguel.PerezAso@nyumc.org

A_{2A}R, A_{2B}R, and A₃R, reviewed in [24]]. In human and murine monocytes/macrophages, the activation of adenosine receptors, particularly A_{2A}R, modulates the production of inflammatory cytokines including TNF- α , IL-10, and IL-12 [25–29]. We therefore analyzed the impact of A_{2A}R activation by the specific agonist CGS26180, as well as with the pro-inflammatory mediator TNF- α , on the molecular clock machinery of the human monocytic THP-1 cell line. The effects described here are, to our knowledge, the first description of the role of adenosine and its receptors in the regulation of circadian pacemakers in the immune system and provide further insight into the effects of inflammation on circadian pacemakers.

MATERIALS AND METHODS

Cell Culture and Stimulation

THP-1 (TIB-202) cells were purchased from American Type Culture Collection (ATCC) and maintained in RPMI 1640 medium (30-2001; ATCC) supplemented with 10 % FBS (Gibco). For the stimulation, cells were thawed and split in every experiment as follows: a new vial from ATCC was thawed into 20 ml of RPMI 1640 medium with 10 % FBS; after 2 days of culture, cells had achieved a concentration of $2.5\text{--}4\times 10^5$ /ml and were then split into 120 ml of medium (passage 1); after 3 days, the cell concentration reached $1\text{--}2\times 10^5$ /ml, and the cells were then spun down and resuspended into 120 ml of medium (passage 2). After 3 days, the confluence was $6\text{--}8\times 10^5$ /ml, and they were then split into 600 ml of medium (passage 3). Three days after (day of the stimulus), the concentration was $2.5\text{--}5\times 10^5$ /ml. Cells were discarded if the concentration was outside the specified range at any of the passages described above.

On the day of study, passage 4 of THP-1 cells was diluted into the appropriate volume of RPMI 1640 medium with 10 % serum to get 120×10^6 cells at 0.8×10^6 /ml, which were then split into 25-cm² flasks with 5 ml on each at 12 PM. Stimulation with CGS21680 (TOCRIS) 100 nM (final) and/or TNF- α (rhTNF- α , R&D Systems) 100 U/ml (final) was begun at 12 AM, and samples were harvested every 4 h. For harvesting, the THP-1 cells were spun down, washed with PBS, and the resulting pellet was immediately frozen at -80°C . The changes in gene expression were studied in four separate independent experiments, and all results reported represent the mean (\pm SEM) changes observed in these experiments.

RNA Extraction and Real-Time Reverse Transcription PCR

After stimulating the THP-1 cells with CGS21680, 100 nM, and/or TNF- α 100 U/ml at the indicated time points, the RNA was extracted and purified using the RNeasy Mini Kit columns (Qiagen) according to the manufacturer's protocol, including sample homogenization with QIAshredder columns (Qiagen) and DNA digestion with RNase-free DNAase set (Qiagen). Following this step, the RNA was reverse transcribed with MuLV Reverse transcriptase (Applied Biosystems) at 2.5 U/ μ l, including in the same reaction the following reagents: RNAase Inhibitor 1 U/ μ l (Applied Biosystems), Random Hexamers 2.5 U/ μ l (Applied Biosystems), MgCl₂ 5 mM (Applied Biosystems), PCR buffer II 1 \times (Applied Biosystems), and dNTPs 1 mM (Applied Biosystems).

For Clock, Bmal1, Cry1, IL-10, IL-12, and actin, relative quantification of gene expression was performed using real-time RT-PCR on Mx3005P Real-Time PCR System (Stratagene) with SYBR Green (Agilent Technologies, 600548) according to the manufacturer's protocol. For Per1, Cry2, hrevErbA1, Per2, and GAPDH, Multiplex relative quantification of gene expression was performed using real-time RT-PCR on Mx3005P Real-Time PCR System (Stratagene) with Brilliant Multiplex QPCR Master Mix (Agilent Technologies). Fluorescence was measured during the annealing step of each cycle. In the initial tests, the PCR products were separated by electrophoresis on agarose gels to verify the size of the amplified product and to check for the presence of primer dimers or nonspecific bands. Single-plex real-time PCR assays were performed as described above with only one set of primers and probe in the amplification reaction. To rule out the possibility of discrepancies between SYBR Green and TaqMan Multiplex technologies, we analyzed one of the genes, Per1, with both technologies and found similar fold changes throughout the 24-h time course in control non-stimulated THP-1 cells, as well as cells stimulated with CGS21680 100 nM or TNF- α 100 U/ml (Supplemental Figure).

Primers and TaqMan Probes' Design and Validation

Multiplex primers and probes were designed using the online software RealTimeDesignTM (Biosearch Technologies) with TaqMan technology. Next, specificity of the primers and probes was assessed by MFEprimer online software [30]. Primers and probe

dimerization was next analyzed by PriDimerCheck online software, and melting temperatures (T_m) were calculated with the Applied Biosystems™ online calculator. For SYBR Green primer design and validation, the same online tools were used, but the initial design was addressed by Primer3 (v.0.4.0). Target genes, primers' and probes' sequences, T_m , and amplicon sizes are shown in Table 1.

Statistical Analysis

Statistical differences were determined using repeated measures ANOVA carried out using GraphPad software on a PC. The alpha nominal level was set at 0.05 in all cases. A P value of <0.05 was considered significant.

RESULTS

$A_{2A}R$ Stimulation Activates the Clock Core Loop of THP-1 Cells

As noted above, the primary anti-inflammatory effects of adenosine are mediated via stimulation of adenosine A_{2A} receptors, and we have previously demonstrated that adenosine A_{2A} receptor stimulation of THP-1 cells suppresses TNF- α and stimulates IL-10 expression [31]. To determine whether stimulation of this receptor also regulates circadian fluctuations in clock proteins, we determined the effects of CGS21680 treatment on circadian gene expression over 24 h. As shown in Fig. 1a, b, $A_{2A}R$ activation promoted a significant increase of both Clock and Bmal1, the main activators of the clock core loop, during the 24-h period studied. While maximal induction of these genes occurred after 8 h (Clock 1.6 ± 0.1 -fold increase and Bmal1 1.6 ± 0.4 -fold increase of control), we found that even after $A_{2A}R$ activation, there were circadian fluctuations for these two genes throughout the entire 24-h period studied.

We next investigated the impact of $A_{2A}R$ activation on expression of the principal clock core loop repressor genes: Cry1, Cry2, Per1, and Per2 (Fig. 1c–f). We found that CGS21680 did not significantly alter either the fluctuations or the expression levels of Cry1, Cry2, or Per1, but $A_{2A}R$ activation did flatten the fluctuations and reduced the expression levels of Per2 throughout the period studied.

Table 1. Target Genes, Primers and Probes Sequences, T_m , and Amplicon Sizes

Target (human)	Technology	Forward primer 5'-3'	Reverse primer 5'-3'	Probe	Probe labeling	Amplicon size (bp)
Actin	SYBRGreen	TCACCCACACTGTGCCCTCTACGA	CAGCGAACCCTGATGCAATGG			295
Clock	SYBRGreen	AAGTTAGGGCTGAAAGACGACG	GAACTCCGAGAAGAGCAGAG			172
Bmal1a	SYBRGreen	GTAACCTCAGTCGCCTCGTC	TAGCTGTGCCCTCTGGTCT			153
Cry1	SYBRGreen	TTGCTTGATGCAGATTGGAG	TTTTTCAGGGAAGCCCTTAA			174
Per1	SYBRGreen	CACCCTGATGACCCACTCTT	GGTAAGGCTGGACTGGATGA			209
IL-10	SYBRGreen	GACTTTAAGGGTTACCTGGGTTG	TCACATGGCCCTTGATGCTG			112
IL-12	SYBRGreen	CCTTGCACTTCTGAAGAGATTGA	TCCACTGTGCTGGTTTAACTTTT			63
GAPDH (1)	TaqMan (Multiplex 1)	GCCCTCAAGCACCACCTTTG	CCACCACTGTTGCTGTAG	CAAGCTCAITTCCTGGTATGACAAAGA	FAM-BHQ1	73
Cry2	TaqMan (Multiplex 1)	GGTGTGCATTCAGAGCAITGG	GGCCGATTTCTTTTCCTCTC	CTTCCCTGTTCCCTCAGCCCCAG	HEX-BHQ1	96
Per1	TaqMan (Multiplex 1)	GCACCAGCTAGACTCCATTC	GGCGATTTCCCACTGGT	TGGACCATCTCCAAGGATCCAT	ROX-BHQ2	46
hrevErbA1	TaqMan (Multiplex 1)	GGGTTCCGTGACCTTTC	TGCGGTTAGGAAACATCAC	TGACCAAGTCACCCTGTAAAGGC	CY5-BHQ2	128
GAPDH (2)	TaqMan (Multiplex 2)	GCCAAGTCACTCCATGACAACT	GGGCCATCCACAGTCTTCTG	TGGTATGTTGGAAGACTATGACCA	FAM-BHQ1	92
Per2	TaqMan (Multiplex 2)	ACCAGGCTGTGACCAACACA	GGCTGGTGGGAAGCAGAT	TGTGAGACCCAGTCTGTTGGTTT	HEX-BHQ1	86




Fig. 1. A_{2A}R stimulation with CGS21680 activates the core loop machinery. THP-1 cells split at 12 pm were analyzed every 4 h starting at 12 am with quantitative real-time RT-PCR. Cells were kept in 10 % serum medium with CGS21680 100 nM, or without the agonist (control), under strict cell growth monitoring. Results show the *x*-fold variations from time 0 (*t*=0) for the mRNA of **a** clock, **b** Bmal, **c** Cry1, **d** Cry2, **e** Per1, and **f** Per2. Data represent mean \pm SEM of four independent experiments. Statistics was performed by ANOVA followed by Newman-Keuls posttest, control vs CGS21680 ****p*<0.001, ***p*<0.01.

TNF- α Increases Bmal and Decreases Cry1 Expression in THP-1 Cells

Previous studies have demonstrated that splenic macrophages secrete TNF- α in a rhythmic fashion governed by a circadian clock within the cell [32] and, conversely, it has also been demonstrated that TNF- α suppresses the expression of clock genes [33]. We therefore sought to analyze the impact of TNF- α on the expression of the clock core activators and inhibitors in the THP-1 cell line. As shown in Fig. 2a, b, TNF- α incubation did not promote significant modification of most clock gene fluctuations, but stimulated a strong and significant increase of Bmal expression with reduced fluctuation during the 24-h period studied. TNF- α incubation dramatically altered Cry1 fluctuations with inversions at 8 and 20 h. For Cry2, which has dampened periodicity when compared to the other clock genes, TNF- α promoted an

increase on expression only after 20 h. TNF- α promoted a slight increase in Per1 expression from 16 to 24 h when compared to control cells and flattened the fluctuations of Per2, although these differences were not significant.

TNF- α +CGS21680 Impact on the Clock Core Loop of THP-1 Is Similar to the TNF- α Alone

Since our research group has previously established that TNF- α treatment potentiates the effect of CGS21680 in THP-1 cells [31], we therefore stimulated the THP-1 cells with both TNF- α and CGS21680 and analyzed the fluctuations of the different components of the clock machinery. As shown in Fig. 3a, TNF- α +CGS21680 induced a similar circadian pattern for clock when compared to the non-stimulated control, and only after 20 h was there a slight increase in expression. On the other hand, TNF- α +CGS21680 stimulated a significant increase of Bmal over




Fig. 2. TNF- α activates the core loop machinery. THP-1 cells split at 12 pm were analyzed every 4 h starting at 12 am with quantitative real-time RT-PCR. Cells were kept in 10 % serum medium with TNF- α 100 U/ml, or without the cytokine (control), under strict cell growth monitoring. Results show the x -fold variations from time 0 ($t=0$) for the mRNA of **a** clock, **b** Bmal, **c** Cry1, **d** Cry2, **e** Per1, and **f** Per2. Data represent mean \pm SEM of four independent experiments. Statistics was performed by ANOVA followed by Newman-Keuls posttest, control vs TNF- α *** $p < 0.001$, * $p < 0.05$.

the 24-h period studied and, similar to the impact of TNF- α alone, the expression of Bmal was not only higher but also exhibited less fluctuations (Fig. 3b).

When we examined the effect of TNF- α +CGS21680 on the clock core loop repressors (Fig. 3c-f), we observed that Cry1 expression was decreased only after 8 h, and that Cry2 was only increased after 12 h. For Per1 and Per2, we observed similar changes to those following TNF- α treatment alone with a slight increase in Per1 mRNA from 16 to 24 h, and Per2 expression was not only decreased but also it presented less fluctuations.

A_{2A}R Activation with CGS21680, but Not TNF- α Incubation, Increases Rev-Erb α in THP-1 Cells

Increasing evidence has established the existence of a stabilizing secondary loop, which is not

required for circadian rhythm generation, but reinforces the primary loop by regulating core components [1]. The nuclear orphan receptor Rev-Erb α , a key component of the secondary loop, has been repeatedly shown to repress Bmal1 transcription through direct binding to the Bmal1 promoter [34]. Because our results suggested that the only core component affected by both CGS21680 and TNF- α was Bmal1, we determined whether Rev-Erb α is regulated by A_{2A}R activation with CGS21680 or TNF- α treatment alone, or in combination. As shown in Fig. 4a-c, CGS21680 stimulated a modest but significant increase of Rev-Erb α expression. On the other hand, TNF- α only decreased Rev-Erb α after 4 h and, similarly, CGS21680+TNF- α reduced the expression levels of Rev-Erb α after 4 h.




Fig. 3. Co-treatment with CGS21680 and TNF- α impact on the core loop machinery. THP-1 cells split at 12 pm were analyzed every 4 h starting at 12 am with quantitative real-time RT-PCR. Cells were kept in 10 % serum medium with CGS21680 100 nM+TNF- α 100 U/ml, or without the agonist and the cytokine (control), under strict cell growth monitoring. Results show the x -fold variations from time 0 ($t=0$) for the mRNA of **a** clock, **b** Bmal, **c** Cry1, **d** Cry2, **e** Per1, and **f** Per2. Data represents mean \pm SEM of four independent experiments. Statistics was performed by ANOVA followed by Newman-Keuls posttest, control vs CGS21680+TNF- α $**p<0.01$.

Impact of TNF- α and CGS21680 Stimulation on IL-10 and IL-12 Expression in THP-1 Cells

We have previously reported that stimulation of the A_{2A}R with CGS21680 selectively inhibits IL-12 release and promotes IL-10 secretion [31], and prior work with murine splenic macrophages indicates that there is cyclic expression of cytokines [32]. Here, we observed that in non-preactivated THP-1 cells, IL-10 but not IL-12 expression fluctuated spontaneously (Fig. 5a). TNF- α treatment stimulated a slight but nonsignificant increase in IL-10 expression from 4 to 8 h (3.2 ± 0.9 -fold increase over control) while inducing a dramatic decrease of IL-12 at the same time points (0.33 ± 0.02 of control; Fig. 5b, c). Stimulation of the A_{2A}R with CGS21680 did not change IL-10 or IL-12 mRNA expression, but co-stimulation with CGS21680 and TNF- α potentiated the effect of TNF- α eliciting a dramatic

increase in IL-10 expression (5.9 ± 2.0 -fold increase over control). The effect of CGS21680+TNF- α co-stimulation on IL-12 expression was identical to that of TNF- α alone.

DISCUSSION

The molecular mechanisms by which clock genes maintain circadian rhythm are becoming increasingly clear. In the immune system, many functions and parameters vary based on the time of day including variation in susceptibility to infection [5] and course of immunologically mediated diseases like RA or asthma [6, 7] highlighting the importance of the circadian clock for health and disease [35]. Consistent with these observations, fully operational autonomous circadian




Fig. 4. CGS21680, but not TNF- α or CGS21680+TNF- α , increases Rev-Erb α expression. THP-1 cells split at 12 pm were analyzed every 4 h starting at 12 am with quantitative real-time RT-PCR. Cells were kept in 10 % serum medium with **a** CGS21680 100 nM, **b** TNF- α 100 U/ml, and **c** CGS21680 100 nM+TNF- α 100 U/ml, or without the agonist and the cytokine (control), under strict cell growth monitoring. Results show the x -fold change for Rev-Erb α mRNA variations from time 0 ($t=0$). Data represent mean \pm SEM of four independent experiments. Statistics was performed by ANOVA followed by Newman-Keuls posttest, control vs CGS21680 * p <0.05.

clockworks function in immunological tissues like spleen, lymph nodes, and resident peritoneal macrophages [32]. In fact, the strength of proinflammatory cytokine production by macrophages in response to bacterial endotoxin is determined by the circadian phase of the macrophage clock rather than by systemic circadian modulators such as rhythmic cortisol levels [36].

There are clear circadian manifestations of RA, a chronic polyarthritis of unknown etiology affecting ~1 %

of the population worldwide, such as morning stiffness, a symptom which is included in the diagnostic criteria for RA [13]. Such circadian characteristics are also seen in the proinflammatory cytokines and disease-specific markers important in RA: IL-1 β and IL-6 are elevated in sera of RA patients reaching peak levels in the early morning [6, 17, 19, 20]. In fact, TNF- α , a major cytokine implicated in RA [37], exhibits a delayed secretion rhythm in patients, with the highest levels measured at 6 am and remaining




Fig. 5. TNF- α and A_{2A}R impact on IL-10 and IL-12 expression. THP-1 cells split at 12 pm were analyzed every 4 h starting at 12 am with quantitative real-time RT-PCR. Cells were kept in 10 % serum medium under strict cell growth monitoring. **a** Results show the *x*-fold variations from time 0 (*t*=0) for the mRNA of IL-10 and IL-12. Impact of TNF- α 100 U/ml and CGS21680 100 nM on **b** IL-10 and **c** IL-12. Data represent mean \pm SEM of four independent experiments. Statistics was performed by ANOVA followed by Newman-Keuls posttest, ****p*<0.001, ***p*<0.01 vs control.

upregulated until 10 am [38] coinciding with morning stiffness in RA [9, 39, 40]. In our studies, we found that TNF- α or costimulation with CGS+TNF- α promotes dramatic changes in IL-10 and IL-12 from 4 am to 8 am, suggesting that signs and symptoms of RA can be modulated by the circadian clock and that, conversely, circadian rhythms modu-

late arthritis [8]. Thus, TNF- α interferes with the expression of clock genes, suggesting that the “TNF- α inflammatory clock gene response” may induce fatigue, a manifestation of CNS circadian dysregulation, diminishing the quality of life in autoimmune diseases [33] and that inhibition of TNF- α improves disabling fatigue in RA [41].




Fig. 6. Diagram depicting the A_{2A}R and TNF- α roles on the intrinsic molecular clockwork of THP-1 cells.

Methotrexate (MTX), the cornerstone drug in the treatment of RA and other rheumatic diseases, promotes the release of adenosine from cells and tissues, and adenosine mediates many of the anti-inflammatory effects of MTX [23]. Moreover, the beneficial effects of MTX have been reported to be reduced in RA patients who drink coffee (caffeine is a well-known adenosine receptor antagonist) [42]. When stimulated, the adenosine A_{2A} receptor increases intracellular cAMP, and cAMP signaling oscillates in a circadian manner, which in turn sustains core oscillation machinery of the circadian clock [43], suggesting a potential link between adverse circadian effects of MTX, such as fatigue, and A_{2A} receptor activation in the CNS after MTX-induced adenosine release [44].

The validation of TNF- α as a therapeutic target in RA encouraged the investigation of signaling pathways regulating its production [45]. The cAMP signaling pathway downregulates TNF- α production and upregulates production of the anti-inflammatory cytokine IL-10 [46, 47]. In the present work we found that, as previously described [26, 48–52], TNF- α stimulation promotes an increase of IL-10 and a marked decrease in IL-12, and these effects are potentiated by coinubation with the A_{2A}R agonist CGS26180 consistent with prior observations [25, 28, 31, 52].

We analyzed the impact of TNF- α and A_{2A}R activation on the clock genes of the human monocytic cell line THP-1. Although circadian genes' expression has not been extensively studied in cultured macrophages or monocytes, it has been previously suggested that altering the fetal bovine serum content from 10 % to either 50 [53] or 0 % [33, 54] serum synchronizes circadian gene expression in cultured mammalian cells [53]. In our preliminary studies, we found that there was no impact of varying the serum content of medium to 0 or 50 % serum changed the periodicity of expression of clock gene in THP-1 cells (not shown) and did not, therefore, shock cells for the experiments described here.

Circadian alterations in symptoms of patients with RA and other inflammatory arthritides correlate with aberrant circadian alterations in levels of TNF- α ; levels of this inflammatory cytokine are upregulated from 6 am to 10 am [38] coinciding with the sign of morning stiffness [9, 39, 40]. It was therefore interesting to note that TNF- α increases Bmal1, but reduces Cry1 and Per2 expression in THP-1 cells, and the greatest effects of cytokine treatment were noted over a short period of time. Activation of A_{2A}R also regulates expression of circadian clock genes with increases in the clock core loop (clock and Bmal1) and downregulation of Per2, the core loop repressor. Prior

experiments have shown that TNF- α potentiates the A_{2A}R impact on IL-10 and IL-12 [31], and similar potentiation was observed for circadian clock genes as well.

The nuclear orphan receptor Rev-Erb α , a key component of the secondary loop, is the major regulator of cyclic Bmal1 transcription and constitutes a molecular link through which components of the negative limb drive antiphase expression of the positive limb [55]. Stimulation of A_{2A}R slightly, but significantly, increased its expression. Since the secondary loop stabilizes, but is not required for circadian rhythm generation [1], our findings suggest that adenosine activation of the A_{2A}R confers additional robustness to the core loop via Rev-Erb α upregulation. On the other hand, neither TNF- α nor CGS21680+TNF- α significantly affected Rev-Erb α levels.

Our results demonstrate, for the first time to our knowledge, that A_{2A}R stimulation activates the intrinsic clockwork machinery of the human monocytic THP-1 cell line by increasing the expression of the core loop activators, clock and Bmal1, while decreasing the expression of the core loop repressor Per2 and confers greater robustness to the circadian phase by increasing the secondary loop repressor Rev-Erb α (summarized in Fig. 6). TNF- α also activates the core loop by increasing Bmal1 expression and decreasing Cry1. On the other hand, A_{2A}R activation does not alter the impact of TNF- α neither on the core nor on the secondary loops here studied. The demonstration that A_{2A}R activation and TNF- α concomitantly regulate the intrinsic circadian clock in immune cells provides an attractive explanation for the observation that methotrexate, which promotes adenosine release, is associated with such adverse circadian effects as fatigue and may therefore shed further light on the anti-inflammatory actions of MTX therapy and may provide new insights to improve the quality of life for RA patients undergoing therapy.

ACKNOWLEDGMENTS

This work was supported by grants from the National Institutes of Health (AR56672, AR56672S1 and AR54897).

REFERENCES

- Hogenesch, J.B., and E.D. Herzog. 2011. Intracellular and intercellular processes determine robustness of the circadian clock. *FEBS Letters* 585(10): 1427–1434.
- Reppert, S.M., and D.R. Weaver. 2002. Coordination of circadian timing in mammals. *Nature* 418(6901): 935–941.
- Yamazaki, S., et al. 2000. Resetting central and peripheral circadian oscillators in transgenic rats. *Science* 288(5466): 682–685.
- Yoo, S.H., et al. 2004. PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. *Proceedings of the National Academy of Sciences of the United States of America* 101(15): 5339–5346.
- Shackelford, P.G., and R.D. Feigin. 1973. Periodicity of susceptibility to pneumococcal infection: Influence of light and adrenocortical secretions. *Science* 182(4109): 285–287.
- Cutolo, M., et al. 2003. Circadian rhythms in RA. *Annals of the Rheumatic Diseases* 62(7): 593–596.
- Sutherland, E.R. 2005. Nocturnal asthma. *The Journal of Allergy and Clinical Immunology* 116(6): 1179–1186. quiz 1187.
- Hashimoto, A., et al. 2010. Mammalian clock gene Cryptochrome regulates arthritis via proinflammatory cytokine TNF- α . *Journal of Immunology* 184(3): 1560–1565.
- Harkness, J.A., et al. 1982. Circadian variation in disease activity in rheumatoid arthritis. *British Medical Journal (Clinical Research Ed.)* 284(6315): 551–554.
- Kowanko, I.C., et al. 1981. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day. *British Journal of Clinical Pharmacology* 11(5): 477–484.
- Kowanko, I.C., et al. 1982. Time of day of prednisolone administration in rheumatoid arthritis. *Annals of the Rheumatic Diseases* 41(5): 447–452.
- Kowanko, I.C., et al. 1982. Domiciliary self-measurement in the rheumatoid arthritis and the demonstration of circadian rhythmicity. *Annals of the Rheumatic Diseases* 41(5): 453–455.
- Arnett, F.C., et al. 1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis and Rheumatism* 31(3): 315–324.
- Pinals, R.S., A.T. Masi, and R.A. Larsen. 1981. Preliminary criteria for clinical remission in rheumatoid arthritis. *Arthritis and Rheumatism* 24(10): 1308–1315.
- Bijlsma, J.W., and J.W. Jacobs. 2009. Methotrexate: Still the anchor drug in RA treatment. *Joint, Bone, Spine* 76(5): 452–454.
- Furst, D.E. 1997. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. *British Journal of Rheumatology* 36(11): 1196–1204.
- Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. *The New England Journal of Medicine* 344(12): 907–916.
- Cutolo, M., R.H. Straub, and F. Buttgerit. 2008. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: Translation from bench to bedside. *Annals of the Rheumatic Diseases* 67(7): 905–908.
- Danis, V.A., et al. 1992. Circulating cytokine levels in patients with rheumatoid arthritis: Results of a double blind trial with sulphasalazine. *Annals of the Rheumatic Diseases* 51(8): 946–950.
- Dasgupta, B., et al. 1992. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. *Journal of Rheumatology* 19(1): 22–25.
- Weinblatt, M.E., et al. 1985. Efficacy of low-dose methotrexate in rheumatoid arthritis. *The New England Journal of Medicine* 312(13): 818–822.
- Chan, E.S., and B.N. Cronstein. 2002. Molecular action of methotrexate in inflammatory diseases. *Arthritis Research* 4(4): 266–273.
- Chan, E.S., and B.N. Cronstein. 2010. Methotrexate—how does it really work? *Nature Reviews. Rheumatology* 6(3): 175–178.
- Gessi, S., et al. 2011. Adenosine receptors in health and disease. *Advances in Pharmacology* 61: 41–75.

25. Hasko, G., *et al.* 2000. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. *The FASEB Journal* 14(13): 2065–2074.
26. Le Moine, O., *et al.* 1996. Adenosine enhances IL-10 secretion by human monocytes. *Journal of Immunology* 156(11): 4408–4414.
27. Le Vraux, V., *et al.* 1993. Inhibition of human monocyte TNF production by adenosine receptor agonists. *Life Sciences* 52(24): 1917–1924.
28. Link, A.A., *et al.* 2000. Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. *Journal of Immunology* 164(1): 436–442.
29. Thiel, M., and A. Chouker. 1995. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-alpha of endotoxin-stimulated human polymorphonuclear leukocytes. *The Journal of Laboratory and Clinical Medicine* 126(3): 275–282.
30. Qu, W., *et al.* 2009. MFEprimer: Multiple factor evaluation of the specificity of PCR primers. *Bioinformatics* 25(2): 276–278.
31. Khoa, N.D., *et al.* 2001. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. *Journal of Immunology* 167(7): 4026–4032.
32. Keller, M., *et al.* 2009. A circadian clock in macrophages controls inflammatory immune responses. *Proceedings of the National Academy of Sciences of the United States of America* 106(50): 21407–21412.
33. Cavadini, G., *et al.* 2007. TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. *Proceedings of the National Academy of Sciences of the United States of America* 104(31): 12843–12848.
34. Yin, L., and M.A. Lazar. 2005. The orphan nuclear receptor Rev-erbalpha recruits the N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene. *Molecular Endocrinology* 19(6): 1452–1459.
35. Takahashi, J.S., *et al.* 2008. The genetics of mammalian circadian order and disorder: Implications for physiology and disease. *Nature Reviews Genetics* 9(10): 764–775.
36. Krieger, D.T. 1975. Rhythms of ACTH and corticosteroid secretion in health and disease, and their experimental modification. *Journal of Steroid Biochemistry* 6(5): 785–791.
37. Semaan, N., *et al.* 2011. miR-346 controls release of TNF-alpha protein and stability of its mRNA in rheumatoid arthritis via tristetraprolin stabilization. *PLoS One* 6(5): e19827.
38. Straub, R.H., and M. Cutolo. 2007. Circadian rhythms in rheumatoid arthritis: Implications for pathophysiology and therapeutic management. *Arthritis and Rheumatism* 56(2): 399–408.
39. Drewes, A.M., *et al.* 1998. Sleep in rheumatoid arthritis: A comparison with healthy subjects and studies of sleep/wake interactions. *British Journal of Rheumatology* 37(1): 71–81.
40. Latman, N.S. 1983. Relation of menstrual cycle phase to symptoms of rheumatoid arthritis. *American Journal of Medicine* 74(6): 957–960.
41. Pollard, L.C., *et al.* 2006. Fatigue in rheumatoid arthritis reflects pain, not disease activity. *Rheumatology (Oxford, England)* 45(7): 885–889.
42. Neshler, G., M. Mates, and S. Zevin. 2003. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. *Arthritis and Rheumatism* 48(2): 571–572.
43. Koyanagi, S., *et al.* 2011. cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the Period2 gene. *Journal of Biological Chemistry* 286(37): 32416–32423.
44. Bernini, J.C., *et al.* 1995. Aminophylline for methotrexate-induced neurotoxicity. *The Lancet* 345(8949): 544–547.
45. Foey, A.D., *et al.* 2003. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: Implications for rheumatoid arthritis. *Arthritis Research & Therapy* 5(6): R317–R328.
46. Kambayashi, T., *et al.* 1995. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. *Journal of Immunology* 155(10): 4909–4916.
47. Meisel, C., *et al.* 1996. Differential regulation of monocytic tumor necrosis factor-alpha and interleukin-10 expression. *European Journal of Immunology* 26(7): 1580–1586.
48. Elbim, C., *et al.* 2001. Intracellular pool of IL-10 receptors in specific granules of human neutrophils: Differential mobilization by proinflammatory mediators. *Journal of Immunology* 166(8): 5201–5207.
49. Hodge-Dufour, J., *et al.* 1998. Inhibition of interferon gamma induced interleukin 12 production: A potential mechanism for the anti-inflammatory activities of tumor necrosis factor. *Proc Natl Acad Sci USA* 95(23): 13806–13811.
50. Keller, C.C., *et al.* 2006. Acquisition of hemozoin by monocytes down-regulates interleukin-12 p40 (IL-12p40) transcripts and circulating IL-12p70 through an IL-10-dependent mechanism: *In vivo* and *in vitro* findings in severe malarial anemia. *Infection and Immunity* 74(9): 5249–5260.
51. Ma, X., *et al.* 2000. Inhibition of IL-12 production in human monocyte-derived macrophages by TNF. *Journal of Immunology* 164(4): 1722–1729.
52. Platzter, C., *et al.* 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. *International Immunology* 7(4): 517–523.
53. Balsalobre, A., F. Damiola, and U. Schibler. 1998. A serum shock induces circadian gene expression in mammalian tissue culture cells. *Cell* 93(6): 929–937.
54. Cardone, L., *et al.* 2005. Circadian clock control by SUMOylation of BMAL1. *Science* 309(5739): 1390–1394.
55. Preitner, N., *et al.* 2002. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. *Cell* 110(2): 251–260.